Other News To Note
• Durata Therapeutics Inc., of Morristown, N.J., reported in vitro data that could help support a clinical program testing antibiotic candidate dalbavancin in pneumonia. In the study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin. Results were presented at IDWeek in San Diego.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST